{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:01:40Z","timestamp":1782925300254,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573450"],"award-info":[{"award-number":["81573450"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81321092"],"award-info":[{"award-number":["81321092"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National\u00a0Basic Research Program of China","doi-asserted-by":"crossref","award":["2015CB910603"],"award-info":[{"award-number":["2015CB910603"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002367","name":"Chinese\u00a0Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Institutes for Drug Discovery and Development of the Chinese\u00a0Academy of Sciences","award":["CASIMM0120152003"],"award-info":[{"award-number":["CASIMM0120152003"]}]},{"name":"Institutes for Drug Discovery and Development of the Chinese\u00a0Academy of Sciences","award":["CASIMM0120153005"],"award-info":[{"award-number":["CASIMM0120153005"]}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of\u00a0Shanghai Municipality","doi-asserted-by":"publisher","award":["16JC1406300"],"award-info":[{"award-number":["16JC1406300"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of\u00a0Shanghai Municipality","doi-asserted-by":"publisher","award":["14431905300"],"award-info":[{"award-number":["14431905300"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of\u00a0Shanghai Municipality","doi-asserted-by":"publisher","award":["16XD1404600"],"award-info":[{"award-number":["16XD1404600"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011198","name":"State Key Laboratory of Drug Research","doi-asserted-by":"crossref","award":["SIMM1601ZZ-03"],"award-info":[{"award-number":["SIMM1601ZZ-03"]}],"id":[{"id":"10.13039\/501100011198","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.canlet.2016.11.010","type":"journal-article","created":{"date-parts":[[2016,11,12]],"date-time":"2016-11-12T11:31:31Z","timestamp":1478950291000},"page":"47-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials"],"prefix":"10.1016","volume":"386","author":[{"given":"Bo","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Shan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Huizi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia-Juan","family":"Huan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Yan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Yan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Wei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Xue","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Hong","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2016.11.010_bib1","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.6b00055","article-title":"An update on poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors: opportunities and challenges in cancer therapy","author":"Wang","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.canlet.2016.11.010_bib2","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/aps.2010.103","article-title":"Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics","volume":"31","author":"He","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.canlet.2016.11.010_bib3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.tips.2006.04.007","article-title":"Emerging cancer therapeutic opportunities target DNA-repair systems","volume":"27","author":"Ding","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.canlet.2016.11.010_bib4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.11.010_bib5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.11.010_bib6","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2014.60.0320","article-title":"Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer","volume":"33","author":"Bang","year":"2015","journal-title":"J.\u00a0Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2016.11.010_bib7","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-1040","article-title":"PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer","author":"Lok","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2016.11.010_bib8","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1021\/jm301825t","article-title":"Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors","volume":"56","author":"Ye","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.canlet.2016.11.010_bib9","unstructured":"A. Zhang, Z.H. Miao, N. Ye, X.J. Huan, Z.L. Song, C.H. Chen, et\u00a0al., Piperazinotriazole Compounds, Preparation Method and Use Thereof in Drug Preparation. WIPO Patent WO 2014\/019468A1."},{"key":"10.1016\/j.canlet.2016.11.010_bib10","unstructured":"A. Zhang, Z.H. Miao, N. Ye, X.J. Huan, Z.L. Song, C.H. Chen, et\u00a0al., Bridged Cyclic Dihydropyridazinones, Preparation Method, and Use Thereof in Drug Preparation. Chinese Patent: CN201210272085.X."},{"key":"10.1016\/j.canlet.2016.11.010_bib11","unstructured":"A. Zhang, Z.H. Miao, N. Ye, X.J. Huan, Z.L. Song, C.H. Chen, et\u00a0al., Fusing Cyclic Dihydropyridazinones, Preparation Method and Use Thereof in Drug Preparation. Chinese Patent: CN201210251601.0."},{"key":"10.1016\/j.canlet.2016.11.010_bib12","unstructured":"A. Zhang, Z.H. Miao, N. Ye, X.J. Huan, Z.L. Song, C.H. Chen, et\u00a0al., Dihydropyridazinone Compounds, Preparation Method, and Use Thereof in Drug Preparation. Chinese Patent: CN 201210489266.8."},{"key":"10.1016\/j.canlet.2016.11.010_bib13","unstructured":"http:\/\/www.chinadrugtrials.org.cn\/eap\/clinicaltrials.searchlist."},{"key":"10.1016\/j.canlet.2016.11.010_bib14","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/j.bmcl.2014.04.061","article-title":"Synthesis of isoquinolinone-based tricycles as novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors","volume":"24","author":"Chen","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.canlet.2016.11.010_bib15","article-title":"Water-soluble PARP1\/2 inhibitor mefuparib hydrochloride elicits potent in\u00a0vitro and in\u00a0vivo anticancer activity, characteristic of high tissue distribution","author":"He","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2016.11.010_bib16","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.11.010_bib17","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1158\/1535-7163.MCT-15-0753","article-title":"Triptolide induces cell killing in multidrug-resistant tumor cells via CDK7\/RPB1 rather than XPB or p44","volume":"15","author":"Yi","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2016.11.010_bib18","doi-asserted-by":"crossref","first-page":"8960","DOI":"10.18632\/oncotarget.3264","article-title":"Dual targeting of microtubule and topoisomerase II by \u03b1-carboline derivative YCH337 for tumor proliferation and growth inhibition","volume":"6","author":"Yi","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2016.11.010_bib19","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1158\/1535-7163.MCT-13-0629","article-title":"MCL-1 degradation mediated by JNK activation via MEKK1\/TAK1-MKK4 contributes to anticancer activity of new tubulin inhibitor MT189","volume":"13","author":"Wang","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2016.11.010_bib20","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ijc.25661","article-title":"MT119, a new planar-structured compound, targets the colchicine site of tubulin arresting mitosis and inhibiting tumor cell proliferation","volume":"129","author":"Zhang","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2016.11.010_bib21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3892\/or.2013.2902","article-title":"Natural and glucosyl flavonoids inhibit poly(ADP-ribose) polymerase activity and induce synthetic lethality in BRCA mutant cells","volume":"31","author":"Maeda","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2016.11.010_bib22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ygyno.2014.03.007","article-title":"Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer","volume":"133","author":"Konstantinopoulos","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2016.11.010_bib23","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1073\/pnas.1416418112","article-title":"Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins","volume":"112","author":"Poruchynsky","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2016.11.010_bib24","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2174\/1574887110666150729125809","article-title":"Clinical trials of poly(ADP-ribose) polymerase inhibitors for cancer therapy: a review","volume":"10","author":"Buege","year":"2015","journal-title":"Rev. Recent Clin. Trials"},{"key":"10.1016\/j.canlet.2016.11.010_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.canlet.2016.11.010_bib26","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1124\/jpet.114.222448","article-title":"Trapping poly(ADP-ribose) polymerase","volume":"353","author":"Shen","year":"2015","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.canlet.2016.11.010_bib27","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1021\/jm5018237","article-title":"Niraparib: a poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination","volume":"58","author":"Jones","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.canlet.2016.11.010_bib28","unstructured":"J. Davis, TESARO's Niraparib Significantly Improved Progression-free Survival for Patients with Ovarian Cancer in Both Cohorts of the Phase 3 NOVA Trial, http:\/\/ir.tesarobio.com\/releasedetail.cfm?ReleaseID=977524."},{"key":"10.1016\/j.canlet.2016.11.010_bib29","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2016.11.010_bib30","unstructured":"A Maintenance Study with Niraparib versus Placebo in Patients with Platinum Sensitive Ovarian Cancer. https:\/\/clinicaltrials.gov\/show\/NCT01847274."},{"key":"10.1016\/j.canlet.2016.11.010_bib31","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N.\u00a0Engl. J. Med."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516306966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516306966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T05:25:24Z","timestamp":1589693124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383516306966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":31,"alternative-id":["S0304383516306966"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2016.11.010","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2016.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}